NAD metabolism fuels human and mouse intestinal inflammation

Gut

Volumn 67, Issue 10, 2018, Pages 1813-1823

  Gerner, Romana R ^a   Klepsch, Victoria ^a   Macheiner, Sophie ^a   Arnhard, Kathrin ^a   Adolph, Timon E ^a   Grander, Christoph ^a   Wieser, Verena ^a   Pfister, Alexandra ^a   Moser, Patrizia ^b   Hermann Kleiter, Natascha ^a   Baier, Gottfried ^c   Oberacher, Herbert ^a   Tilg, Herbert ^a   Moschen, Alexander R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; DAPORINAD; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 6; TUMOR NECROSIS FACTOR; ACRYLAMIDE DERIVATIVE; GASTROINTESTINAL AGENT; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL INFILTRATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; DRUG EFFICACY; DRUG RESPONSE; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INNATE IMMUNITY; LAMINA PROPRIA; MACROPHAGE; MALIGNANT NEOPLASM; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; ANIMAL; COLON TUMOR; DRUG EFFECT; ENERGY METABOLISM; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; ULCERATIVE COLITIS;

ACRYLAMIDES; ANIMALS; CELL DIFFERENTIATION; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DEXAMETHASONE; ENERGY METABOLISM; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; INTESTINAL MUCOSA; MACROPHAGES; MICE; MONOCYTES; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES;

EID: 85042566641     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314241     Document Type: Article

References (53)

1. Kaser A, Zeissig S, Blumberg RS, et al. Inflammatory bowel disease. Annu Rev /mmunol 2010;28:573-621.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Col/t/s 2012;6:991-1030.
4. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Col/t/s 2010;4:28-62.
5. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N EnglJ Med 2016;375:1946-60.
6. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
7. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Col/t/s 2010;4:355-66.
8. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27.
9. Garedew A, Henderson SO, Moncada S. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ 2010;17:1540-50.
10. Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010;115:4742-9.
11. Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. J Immunol 2010;184:4062-8.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
13. Schreiber V, Dantzer F, Ame JC, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28.
14. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13.
15. Partida-Sanchez S, Gasser A, Fliegert R, et al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol 2007;179:7827-39.
16. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab 2015;22:31-53.
17. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J /mmunol 2002;32:3225-34.
18. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Cl/n /nvest 2004;113:1318-27.
19. Meier FM, Frommer KW, Peters MA, et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J B/ol Chem 2012;287:28378-85.
20. El-Mesallamy HO, Kassem DH, El-Demerdash E, et al. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011;60:63-70.
21. Galli U, Travelli C, Massarotti A, et al. Medicinal chemistry of nicotinamide 21 phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem 2013;56:6279-96.
22. Moschen AR, Kaser A, Enrich B, et alVisfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
23. Starr AE, Deeke SA, Ning Z, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. Gut 2017;66.
24. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
25. Moschen AR, Gerner R, Schroll A, et al. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. Hepatology 2011;54:675-86.
26. Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EA PLoS One 2009;4:e7897.
27. Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 2012;47:519-30.
28. Moschen AR, Gerner RR, Wang J, et al. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe 2016;19:455-69.
29. Rongvaux A, Galli M, Denanglaire S, et al. Nicotinamide phosphoribosyl transferase/ pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008;181:4685-95.
30. Shmuel-Galia L, Aychek T, Fink A, et al. Neutralization of pro-inflammatory monocyt by targeting TLR2 dimerization ameliorates colitis. Emfjo J 2016;35:685-98.
31. Bain CC, Scott CL, Uronen-Hansson H, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013;6:498-510.
32. Busso N, Karababa M, Nobile M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008;3:e2267.
33. Hassa PO, Haenni SS, Buerki C, et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem 2005;280:40450-64.
34. Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009;136:62-74.
35. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anticancer therapy. Eur J Cancer 2006;42:717-27.
36. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 2010;16:1913-20.
37. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7.
38. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008;283:34833-43.
39. Van Gool F, Galli M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 2009;15:206-10.
40. Chiarugi A, Dolle C, Felici R, et al. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012;12:741-52.
41. Carter L, Morgan R, Lesch C, et al. Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease. Journal of Crohns & Col/t/s 2016;10:S38-S9.
42. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003;544:74-8.
43. Larmonier CB, Shehab KW, Laubitz D, et al. Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice. J B/ol Chem 2016;291:8918-30.
44. Jagtap P, Szabo C, Poly SC. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
45. Boughton-Smith NK, Evans SM, Hawkey CJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993;342:338-e2.
46. Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996;1 1 1:871-85.
47. Brunyanszki A, Olah G, Coletta C, et al. Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the 3-adrenoceptor/cAMP/protein kinase A axis during oxidative stress. Mol Pharmacol 2014;86:450-62.
48. Chen X, Lu Y, Zhang Z, et al. Intercellular interplay between Sirt1 signalling and cell metabolism in immune cell biology. Immunology 2015;145:455-67.
49. Sandoval-Montes C, Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol 2005;77:513-21.
50. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
51. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012;15:432-7.
52. Venter G, Oerlemans FT, Willemse M, et al. NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages. PLoS One 2014;9:e97378.
53. Holen K, Saltz LB, Hollywood E, et al. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.